Dechra Pharmaceuticals PLC acquired the entire share capital of Venco Saúde Animal.

The acquisition provides Dechra a strategically significant presence in the rapidly growing Brazilian and South American markets.

Venco has a wide portfolio of vaccines and other products of animal origin (FAP), which it sells predominantly in Brazil, and also in other South American and international markets. It also has a small range of vaccines and pharmaceutical products from pet animal products (PAC), which are sold mainly in the Brazilian market. Overall, it has more than 200 current product registrations. Brazil is the fourth largest FAP market in the world, and Vaccines is the fastest growing therapeutic area within FAP in the world.

The acquisition provides Dechra a strategically significant presence in the rapidly growing Brazilian and South American markets.The Londrina site, in the state of Paraná, houses all of Venco's business functions, including product development, manufacturing, sales and marketing operations and regulatory affairs. The site has enjoyed a significant recent investment period in manufacturing operations, which has considerably improved facilities that have obtained regulatory licenses to operate.

Dechra will invest significantly over the next 2-3 years to develop the business and its presence in South America, continue to develop Venco's existing pipeline and registrations, register Dechra's relevant products and establish the Dechra brand in the region.

 

All transactions